| Oct 29 |
Looking Into Kezar Life Sciences's Recent Short Interest
|
| Oct 28 |
Kezar Life Sciences announces 1-for-10 reverse stock split
|
| Oct 28 |
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
|
| Oct 18 |
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
|
| Oct 17 |
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
|
| Oct 17 |
Kezar stock falls 11% after board rejects Concentra offer (update)
|
| Oct 17 |
Kezar discontinues development of zetomipzomib for lupus nephritis
|
| Oct 17 |
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
|
| Oct 17 |
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
|
| Oct 17 |
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
|
